EUCTR2012-002435-28-NL进行中（未招募）不适用
A phase I/II minor histocompatibility antigen” (mHag)-based Dendritic cell vaccination trial after allogeneic Stem Cell Transplantation to improve the safety and efficacy of donor Lymphocyte infusions - mHag donor DC vaccination in hematological malignancy
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with low grade, intermediate and high grade non Hodgkin lymphoma (NHL), M.Hodgkin, Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Myelodysplasia (MDS) and proven residual disease (including as determined by disease specific of patient specific PCR) minimally 6 months after Allogeneic Stem Cell transplantation (Allo-SCT) and subsequent persistent disease after a first pre-emptive DLI or patients with relapsed haematological disease after Allo-SCT and persistent disease after a first therapeutic DLI.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. WHO performance 3-4
- •2. Presence of severe cardiac hepatic, renal, metabolic disease
- •3. Rapidly progressive disease
- •4. No measurable disease
- •5. Life expectancy > 3 months
研究者
相似试验
已完成
2 期
A phase I/II *minor histocompatibility antigen (mHag)-based Dendritic cell (DC) vaccination trial after allogeneic Stem Cell Transplantation (allo-SCT) to improve the safety and efficacy of donor lymphocyte infusions.bone marrow and lymphatic organscancers of the bloodhematological malignacy10035227NL-OMON37500niversitair Medisch Centrum Utrecht30
撤回
2 期
A phase I/II *minor histocompatibility antigen UTA2-1 loaded, PD-L silenced Dendritic cell vaccination trial after allogeneic Stem Cell Transplantation to improve the safety and efficacy of Donor Lymphocyte Infusions.hematological B cell malignancies blood cell cancer10027656NL-OMON43853Vrije Universiteit Medisch Centrum12
进行中（未招募）
1 期
Tumor Antigen loaded Dendritic Cell Vaccination for hematological malignancies after allogeneic transplantatioMultiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), non Hodgkin lymphoma (nHL)(any grade), Hodgkin’s lymphoma (HL).MedDRA version: 18.1Level: LLTClassification code 10020309Term: Hodgkin's disease, unspecified typeSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10066703Term: Non-Hodgkin's lymphoma progressionSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10068919Term: B-cell chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2015-003554-41-NLVU University Medical Center12
已完成
1 期
Predetermined Minor Histocompatibility Antigen-based Therapeutic or Prophylactic Peptide Vaccinations for Patients with Recurred Malignancies or Patients with High-Risk Malignancies Follwoing Allogeneic Hematopoietic Cell Transplantation.(1) Therapeutic vaccine: Any hematological malignancies recurred after allogineic hematopoietic transplanation as follows (RAEB, CMML, AML, ALL, CML, Multiple Myeloma, NHL). (2) Prophylactic vaccine: Hematological malignancies with high risk of relapse after allogineic hematopoietic transplanation as follows (RAEB, CMML, AML in >=3CR/non-CR or any AML with M0/M6/M7 FAB type, ALL in >=2CR/non-CR, CML in >=2CP or >=AP, Multiple Myeloma in PD, NHL in non-CR).JPRN-UMIN000000872Aichi Cancer Center Research Institute12
已完成
不适用
Vaccination with minor histocompatibility antigen-loaded donor DC vaccines to boost graft-versus-tumor immunity after allogeneic stem cell transplantation (a phase I study)blood cell cancerhematological malignancies10027656NL-OMON40014niversitair Medisch Centrum Sint Radboud10